Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Early-life blood pressure and midlife brain and cognitive health: tests in two birth cohorts.

Brain communications·2026
Same author

Plasma pTau181 is associated with subjective cognitive concerns but not objective cognitive decline or structural brain integrity measures in midlife.

GeroScience·2026
Same author

Letter to the Editor regarding 'Optimising brain health: Getting ambitious about prevention from midlife'.

The Australian and New Zealand journal of psychiatry·2026
Same author

Replicated evidence for an accelerated rate of whole-body aging in schizophrenia.

Psychological medicine·2026
Same author

Shared genetic architecture of brain age gap across 30 cohorts worldwide.

medRxiv : the preprint server for health sciences·2026
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Ashleigh Barrett-Young1, Erin E Cawston2, Brigid Ryan3

  • 1University of Otago, Dunedin, Otago, New Zealand.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

化陶 (pTau181) 度在中年成年人中存在很大差异. 这种阿尔茨海默病生物标志物可能会在认知衰退之前提前增加,这表明潜在的临床前检测.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物研究 生物标志物研究
  • 老龄化研究研究.

背景情况:

  • 血pTau181是已知的阿尔茨海默病 (AD) 生物标志物,但其在中年人群中的临床前实用性尚不清楚.
  • 在以社区为基础的中年人群中研究血pTau181对于了解早期AD风险指标至关重要.

研究的目的:

  • 确定血pTau181水平与中年人群中阿尔茨海默病 (AD) 风险指标之间的关联.
  • 探索血pTau181作为阿尔茨海默病早期,临床前生物标志物的潜力.

主要方法:

  • 利用了来自尼丁多学科健康和发展研究的数据,评估了45岁的1037名个人.
  • 使用Simoa技术测量了血pTau181并收集了MRI数据.
  • 评估了多个时间点的认知能力,并计算了衰老的复合速度.

主要成果:

  • 在856名被评估的参与者中观察到广泛的血pTau181水平.
  • 与女性相比,男性的pTau181水平显著更高,不包括患有脏疾病的人.
  • 血pTau181与认知功能,脑结构 (MRI) 或衰老生物标志物之间没有发现显著的关联.

结论:

  • 广泛的pTau181范围表明,阿尔茨海默病 (AD) 血液生物标志物可能在中年时升高,可能会在临床症状之前出现.
  • 中年期的血pTau181可能是阿尔茨海默病风险的早期指标,需要进一步的纵向研究.
  • 未来的评估将确定中年血pTau181是否预测晚年AD发病.